Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitors
Pharma
GSK trial result mirrors Merck's problem in ovarian cancer
Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
Angus Liu
Dec 20, 2024 10:46am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
Where's Lynparza in AZ's narrow Imfinzi endometrial cancer nod?
Jun 17, 2024 11:24am
AACR: Detailed data spark hope for Merck combo in NSCLC
Apr 9, 2024 1:16pm
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
